121 related articles for article (PubMed ID: 2139230)
1. Enhanced antibody response in the presence of partial adenosine deaminase inhibition.
Hoffman EA; Kopp WC; Moat AG
Proc Soc Exp Biol Med; 1990 May; 194(1):36-42. PubMed ID: 2139230
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of deoxyadenosine toxicity in human lymphoid cells in vitro: relevance to the therapeutic use of inhibitors of adenosine deaminase.
Lee N; Russell N; Ganeshaguru K; Jackson BF; Piga A; Prentice HG; Foa R; Hoffbrand AV
Br J Haematol; 1984 Jan; 56(1):107-19. PubMed ID: 6231047
[TBL] [Abstract][Full Text] [Related]
3. Human B lymphocytes and thymocytes but not peripheral blood mononuclear cells accumulate high dATP levels in conditions simulating ADA deficiency.
Goday A; Simmonds HA; Morris GS; Fairbanks LD
Biochem Pharmacol; 1985 Oct; 34(19):3561-9. PubMed ID: 3876835
[TBL] [Abstract][Full Text] [Related]
4. Inability of poly-ADP-ribosylation inhibitors to protect peripheral blood lymphocytes from the toxic effects of ADA inhibition.
Ganeshaguru K; Piga A; Latini L; Hoffbrand AV
Adv Exp Med Biol; 1989; 253B():251-8. PubMed ID: 2532859
[TBL] [Abstract][Full Text] [Related]
5. Influence of treatment with 3'-deoxyadenosine associated deoxycoformycin on hematological parameters and activity of adenosine deaminase in infected mice with Trypanosoma evansi.
Dalla Rosa L; Da Silva AS; Ruchel JB; Gressler LT; Oliveira CB; França RT; Lopes ST; Leal DB; Monteiro SG
Exp Parasitol; 2013 Oct; 135(2):357-62. PubMed ID: 23933282
[TBL] [Abstract][Full Text] [Related]
6. Effects of deoxyadenosine on the activation of ADA inhibited T & B cells.
Webster AD; Ip H; Pereira S
Clin Exp Immunol; 1982 Dec; 50(3):587-95. PubMed ID: 6299634
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of deoxyadenosine-induced catabolism of adenine ribonucleotides in adenosine deaminase-inhibited human T lymphoblastoid cells.
Bagnara AS; Hershfield MS
Proc Natl Acad Sci U S A; 1982 Apr; 79(8):2673-7. PubMed ID: 6283540
[TBL] [Abstract][Full Text] [Related]
8. Establishment and characterization of adenosine deaminase-deficient human T cell lines.
Kohn DB; Mitsuya H; Ballow M; Selegue JE; Barankiewicz J; Cohen A; Gelfand E; Anderson WF; Blaese RM
J Immunol; 1989 Jun; 142(11):3971-7. PubMed ID: 2497184
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of adenosine deaminase leads to enhanced antibody responses in the mouse.
Nicholson JK; Gordon DS; McDougal JS
Cell Immunol; 1983 Jul; 79(2):320-33. PubMed ID: 6347398
[TBL] [Abstract][Full Text] [Related]
10. Opposite effects of recombinant interferon-alpha A and deoxycoformycin on adenosine deaminase activity in the Daudi B lymphoblastoid cell line.
Faltynek CR
Blood; 1988 Jan; 71(1):59-64. PubMed ID: 3257147
[TBL] [Abstract][Full Text] [Related]
11. The effects of ADA inhibition on B cell differentiation in the rat.
Barton RW
Adv Exp Med Biol; 1986; 195 Pt A():525-9. PubMed ID: 3524140
[No Abstract] [Full Text] [Related]
12. Synergistic effect of 3'-deoxyadenosine N1-oxide and adenosine deaminase inhibitors on growth of Ehrlich ascites tumor cells in vivo.
Svendsen KR; Overgaard-Hansen K; Frederiksen S
Cancer Chemother Pharmacol; 1988; 21(1):35-9. PubMed ID: 3257721
[TBL] [Abstract][Full Text] [Related]
13. The effects of an induced adenosine deaminase deficiency on T-cell differentiation in the rat.
Barton RW
Cell Immunol; 1985 Oct; 95(2):297-310. PubMed ID: 3876160
[TBL] [Abstract][Full Text] [Related]
14. Conversion of a stem cell leukemia from a T-lymphoid to a myeloid phenotype induced by the adenosine deaminase inhibitor 2'-deoxycoformycin.
Hershfield MS; Kurtzberg J; Harden E; Moore JO; Whang-Peng J; Haynes BF
Proc Natl Acad Sci U S A; 1984 Jan; 81(1):253-7. PubMed ID: 6607471
[TBL] [Abstract][Full Text] [Related]
15. Adenosine-deaminase-associated immunodeficiency. I. Differential sensitivities of lymphocyte subpopulations exposed to 2-deoxycoformycin in vivo.
Bagasra O; Howeedy A; Pomerantz RJ
Clin Exp Immunol; 1992 Jun; 88(3):383-8. PubMed ID: 1535036
[TBL] [Abstract][Full Text] [Related]
16. Deoxyadenosine triphosphate accumulation in erythrocytes of deoxycoformycin-treated mice.
Smith CM; Henderson JF
Biochem Pharmacol; 1982 Apr; 31(8):1545-51. PubMed ID: 6980005
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of adenosine triphosphate catabolism induced by deoxyadenosine and by nucleoside analogues in adenosine deaminase-inhibited human erythrocytes.
Bontemps F; Van den Berghe G
Cancer Res; 1989 Sep; 49(18):4983-9. PubMed ID: 2788493
[TBL] [Abstract][Full Text] [Related]
18. Biochemical changes induced in hairy-cell leukemia following treatment with the adenosine deaminase inhibitor 2'-deoxycoformycin.
Johnston JB; Begleiter A; Pugh L; Leith MK; Wilkins JA; Cavers DJ; Israels LG
Cancer Res; 1986 Apr; 46(4 Pt 2):2179-84. PubMed ID: 2418965
[TBL] [Abstract][Full Text] [Related]
19. Energy metabolism in adenosine deaminase-inhibited human erythrocytes.
Buc HA; Thuillier L; Hamet M; Garreau F; Moncion A; Pérignon JL
Clin Chim Acta; 1986 Apr; 156(1):61-9. PubMed ID: 3486057
[TBL] [Abstract][Full Text] [Related]
20. Selective immunotoxic effects in mice treated with the adenosine deaminase inhibitor 2'-deoxycoformycin.
Luebke RW; Lawson LD; Rogers RR; Riddle MM; Rowe DG; Smialowicz RJ
Immunopharmacology; 1987 Feb; 13(1):25-35. PubMed ID: 2952620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
